Sinusitis News and Research

Latest Sinusitis News and Research

FDA approves change to prescribing information for Gilead Sciences' Letairis

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved a change to the prescribing information for Letairis (ambrisentan 5 mg and 10 mg tablets), the company's once-daily treatment to improve exercise ability and delay clinical worsening in pulmonary arterial hypertension (PAH, WHO Group 1) patients with predominantly WHO Functional Class II-III symptoms.

5 Mar 2011

Depression negatively impacts outcomes of care in patients with CRS: New research

Depression is a common problem in patients with chronic rhinosinusitis and negatively impacts patients' symptom burden, ability to function, and quality of life, according to new research published in the March 2011 issue of Otolaryngology - Head and Neck Surgery.

1 Mar 2011

FDA clears Entellus Medical's new FinESS Endoscope

Entellus Medical, a Minnesota-based medical technology company, announced today that the U.S. Food and Drug Administration cleared the company's new FinESS Endoscope.

23 Feb 2011

Entellus Medical enters license agreement with Acclarent to resolve patent lawsuit

Entellus Medical today announced that it has entered into a licensing agreement with Acclarent, Inc. in order to resolve their patent lawsuit. The license agreement is royalty bearing to Acclarent.

18 Feb 2011

Experts say signs and treatment of bacterial infection often misunderstood

According to the Canadian Foundation for Infectious Diseases, antibiotics are the second most frequently prescribed class of drugs - second only to pain relievers. Yet most people don't know the difference between a true bacterial infection, like chronic bronchitis that can be treated with antibiotics — and viruses like the common cold, which cannot.

17 Feb 2011

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

Teva Pharmaceutical Industries Ltd. today announced results from a Phase III study of QNAZE™ (beclomethasone dipropionate [BDP]) HFA, its nasal aerosol corticosteroid in development for the treatment of perennial allergic rhinitis (PAR) and seasonal allergic rhinitis (SAR).

10 Feb 2011

Clinical Decision Support Systems help reduce unnecessary CT and MRI scans

Researchers from Virginia Mason Medical Center in Seattle, WA, have found that clinical decision support systems can help reduce inappropriate medical imaging, including unnecessary computed tomography (CT) and magnetic resonance imaging (MRI) scans, according to a study in the January issue of the Journal of the American College of Radiology (www.jacr.org).

4 Jan 2011

SinoFresh, Green Valley Drug enter marketing relationship for Homeopathic Antiseptic Nasal Spray

SinoFresh® HealthCare, Inc., is pleased to announce that its marketing division has secured an agency marketing relationship with Green Valley Drug, the largest medical supplier in Southern Nevada with a significant pharmacy and medical customer base in the western U.S.

3 Jan 2011

CF patients with normal to mildly impaired lung function may benefit from new investigational drug

Cystic fibrosis patients with normal to mildly impaired lung function may benefit from a new investigational drug designed to help prevent formation of the sticky mucus that is a hallmark of the disease, according to researchers involved in a phase 3 clinical trial of the drug.

19 Dec 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

ViroPharma Incorporated today announced data in four poster presentations and two oral presentations relating to Cinryze (C1 esterase inhibitor [human]) at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), November 11 through 16 in Phoenix, Ariz.

16 Nov 2010

Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting

Teva Pharmaceutical Industries Ltd. today announced results from a Phase III study of QNAZE (beclomethasone dipropionate [BDP]) HFA, a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR), that demonstrated significantly greater symptom relief compared with placebo.

15 Nov 2010

Abbott presents results of 2 pivotal HUMIRA studies at American College of Rheumatology meeting

Today, Abbott presents results from a pooled analysis of two pivotal HUMIRA® (adalimumab) studies, which look at patients with early and long-standing moderate to severe rheumatoid arthritis (RA), at the American College of Rheumatology meeting in Atlanta.

10 Nov 2010

Afinitor tablets decrease size of SEGA associated with tuberous sclerosis

The New England Journal of Medicine (NEJM) today published a study that found patients taking Afinitor (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS).

4 Nov 2010

Acton submits Manufacturing Supplement to FDA for AEROSPAN Inhalation Aerosol

Acton Pharmaceuticals, Inc. today announced that it has submitted to the U.S. Food and Drug Administration (FDA), a Manufacturing Supplement to the previously approved AEROSPAN Inhalation Aerosol NDA.

4 Nov 2010

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

AstraZeneca announced today that results from TITAN, a 12-week study of SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol in African American patients with moderate to severe persistent asthma, showed significant improvement in lung function for patients taking SYMBICORT compared with those using budesonide alone.

3 Nov 2010

Enrollment complete in ViroPharma's Phase 2 study evaluating subcutaneous delivery of Cinryze

ViroPharma Incorporated today announced that it has completed enrollment in its Phase 2 study evaluating subcutaneous delivery of Cinryze™ (C1esterase inhibitor [human]). This multi-center, open-label, multi-dose Phase 2 study is designed to evaluate the safety, pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze in adolescent and adult subjects with hereditary angioedema (HAE).

25 Oct 2010

FDA issues complete response letter for ViroPharma's Cinryze

ViroPharma Incorporated today announced the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding Cinryze (C1 Esterase Inhibitor [Human]) industrial scale manufacturing expansion activities. The FDA has requested additional information related to observations from the pre-approval inspection and review of the technical processes.

25 Oct 2010

Study investigates link between cough and reflux events using sound recording device

Coughing episodes are closely related to gastroesophageal reflux symptoms in patients who experience chronic cough, irrespective of other diagnoses, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

28 Sep 2010

Entellus Medical announces Clinic versus OR study results for chronic sinusitis

Entellus Medical, a Minnesota based medical technology company, shared the results of a 12-month study entitled "Clinic versus OR A Comparative Analysis of Ostial Dilation for CRS," presented on September 25th during the 56th annual meeting of the American Rhinologic Society in Boston, Mass.

27 Sep 2010

Sinusitis News and Research

Latest Sinusitis News and Research

FDA approves change to prescribing information for Gilead Sciences' Letairis

Depression negatively impacts outcomes of care in patients with CRS: New research

FDA clears Entellus Medical's new FinESS Endoscope

Entellus Medical enters license agreement with Acclarent to resolve patent lawsuit

Experts say signs and treatment of bacterial infection often misunderstood

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

Clinical Decision Support Systems help reduce unnecessary CT and MRI scans

SinoFresh, Green Valley Drug enter marketing relationship for Homeopathic Antiseptic Nasal Spray

CF patients with normal to mildly impaired lung function may benefit from new investigational drug

VYTORIN reduces major vascular events in patients with chronic kidney disease

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting

Abbott presents results of 2 pivotal HUMIRA studies at American College of Rheumatology meeting

Afinitor tablets decrease size of SEGA associated with tuberous sclerosis

Acton submits Manufacturing Supplement to FDA for AEROSPAN Inhalation Aerosol

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

Enrollment complete in ViroPharma's Phase 2 study evaluating subcutaneous delivery of Cinryze

FDA issues complete response letter for ViroPharma's Cinryze

Study investigates link between cough and reflux events using sound recording device

Entellus Medical announces Clinic versus OR study results for chronic sinusitis

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Sinusitis News and Research

Latest Sinusitis News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in